LINC02389/miR-7-5p Regulated Cisplatin Resistance of Non-Small-Cell Lung Cancer via Promoting Oxidative Stress

Figure 4

(a) LINC02389 expression in the nucleus and cytoplasma in A549-R. (b) miR-7-5p expression in A549 and HCC827 compared with MRC5. (c) miR-7-5p expression in recurrent and nonrecurrent non-small-cell lung cancer patients. (d) The correlation between miR-7-5p and LINC02389 expressions in non-small-cell lung cancer patients. (e) miR-7-5p expression in A549-R compared with A549. (f) Knockdown of miR-7-5p in A549-R. (g) CCK-8 assay to evaluate the effect of miR-7-5p knockdown in IC50 of A549-R to cisplatin. (h) Upregulation of miR-7-5p in A549-R. (i) CCK-8 assay to evaluate the effect of miR-7-5p upregulation in IC50 of A549-R to cisplatin.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)